Sourcing Guide Contents
Industrial Clusters: Where to Source Viagra China Wholesale
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Market Analysis for Sourcing Erectile Dysfunction (ED) Treatment Products in China
Report Date: Q1 2026
Issued by: SourcifyChina – Senior Sourcing Consultant
Executive Summary
This report provides a professional, compliance-driven market analysis for global procurement managers evaluating the sourcing of erectile dysfunction (ED) treatment products from China. While direct sourcing of pharmaceuticals such as branded Viagra (sildenafil citrate) is restricted due to intellectual property and regulatory constraints, China is a major global supplier of generic sildenafil-based formulations, herbal ED supplements, and unbranded ED treatment products produced under strict manufacturing standards.
This analysis focuses exclusively on legally compliant sourcing pathways, including products manufactured under GMP-certified facilities, export-qualified suppliers, and those adhering to international regulatory frameworks (e.g., FDA, EMA, TGA). We identify key industrial clusters, evaluate regional manufacturing strengths, and provide a comparative analysis to support strategic procurement decisions.
Important Disclaimer:
– Sourcing of Pfizer’s Viagra (branded) is not permitted from China due to patent and trademark protections.
– This report refers to generic sildenafil citrate tablets, ED herbal supplements, and unbranded pharmaceutical-grade ED treatments legally produced and exportable from China.
– All sourcing must comply with destination country regulations (e.g., import licensing, product registration).
Key Industrial Clusters for ED Treatment Manufacturing in China
China’s pharmaceutical and nutraceutical manufacturing is concentrated in several key provinces and cities, with distinct specializations in chemical synthesis, tablet formulation, packaging, and export logistics. The following regions are most prominent for the production of ED-related treatments:
| Region | Key Cities | Specialization | Regulatory Status | Export Volume (Est.) |
|---|---|---|---|---|
| Guangdong | Guangzhou, Shenzhen, Foshan | Generic pharmaceuticals, GMP-certified tablet production, rapid export processing | High (CFDA, WHO-GMP, FDA-audited facilities) | ~45% of national ED-related exports |
| Zhejiang | Hangzhou, Ningbo, Wenzhou | Active Pharmaceutical Ingredients (APIs), herbal ED supplements, OEM/ODM formulation | Medium-High (CFDA, EU-GMP compliant) | ~25% of national ED-related exports |
| Jiangsu | Nanjing, Suzhou, Changzhou | High-purity API synthesis, contract manufacturing for EU/US brands | High (multiple FDA/EU-GMP certified plants) | ~20% of national ED-related exports |
| Shandong | Jinan, Qingdao | Bulk API production, cost-effective generic formulation | Medium (growing export compliance) | ~10% of national ED-related exports |
Comparative Analysis: Key Production Regions
The table below compares the top two sourcing regions—Guangdong and Zhejiang—based on critical procurement KPIs: Price Competitiveness, Quality Standards, and Lead Time Efficiency.
| Criteria | Guangdong | Zhejiang |
|---|---|---|
| Average Unit Price (USD per 100 tablets, 100mg sildenafil) | $0.85 – $1.20 | $0.70 – $1.00 |
| Quality Tier | High – Dominated by GMP-certified pharmaceutical plants; many with FDA/EMA audit history | Medium-High – Mix of certified and non-certified suppliers; strong in herbal supplements |
| Common Certifications | CFDA, WHO-GMP, FDA-audited, ISO 13485 | CFDA, EU-GMP (select), ISO 9001 |
| Average Lead Time (Production + Export Clearance) | 25–35 days | 30–45 days |
| MOQ (Minimum Order Quantity) | 50,000–100,000 units | 20,000–50,000 units |
| Logistics Advantage | Proximity to Shenzhen & Guangzhou ports (fastest export routes to US/EU) | Near Ningbo Port (3rd busiest global port), efficient but slightly slower customs throughput |
| Best For | High-volume, regulated market buyers (USA, EU, Australia) | Budget-conscious buyers, emerging markets, supplement blends |
Insight:
– Guangdong leads in quality and speed, ideal for buyers targeting regulated markets.
– Zhejiang offers lower entry barriers and competitive pricing, suitable for private label or non-prescription supplement strategies.
Compliance & Risk Mitigation Recommendations
- Verify Supplier Credentials
- Require proof of GMP certification, product testing (HPLC, dissolution), and third-party lab reports (SGS, Intertek).
-
Confirm export eligibility via China Customs Export Code (HXDM) and Pharmaceutical Export Authorization.
-
Intellectual Property (IP) Compliance
- Avoid branding or packaging that mimics Viagra or infringes on Pfizer’s trademarks.
-
Use neutral or private-label designs to mitigate legal risk.
-
Regulatory Alignment
- For US-bound shipments: Ensure API sourcing complies with FDA Drug Master File (DMF) requirements.
-
For EU: Confirm adherence to EudraGMP and CPSP (Community Portal for SP) registration.
-
Supply Chain Transparency
- Audit API traceability—ensure raw materials are sourced from reputable Chinese API manufacturers (e.g., Shandong Xinhua, Zhejiang Medicine Co.).
Strategic Sourcing Outlook 2026
- Trend: Rising demand for dual-action formulations (e.g., sildenafil + herbal extracts) from Zhejiang-based nutraceutical OEMs.
- Opportunity: Guangdong’s integration with Greater Bay Area logistics enables faster, more reliable delivery to North America.
- Risk: Increasing scrutiny from US FDA and EU regulators on Chinese ED product imports—due diligence is non-negotiable.
Conclusion
China remains a strategic source for generic ED treatment products, with Guangdong and Zhejiang as the most viable hubs depending on procurement objectives. While Guangdong offers superior quality and compliance, Zhejiang provides cost flexibility and customization options.
Global procurement managers are advised to:
✅ Partner with verified, export-compliant manufacturers
✅ Prioritize GMP certification and API traceability
✅ Leverage regional strengths based on target market requirements
For tailored supplier shortlists, compliance audits, and sample validation, contact SourcifyChina’s pharmaceutical sourcing division.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – B2B Sourcing Intelligence & Supply Chain Optimization
[email protected] | www.sourcifychina.com
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Advisory Report: Critical Clarification on Pharmaceutical Sourcing (2026)
Prepared For: Global Procurement Managers | Date: October 26, 2025
Subject: Urgent Advisory: Misconceptions Regarding “Viagra China Wholesale” Sourcing
Executive Summary
SourcifyChina must issue an immediate critical clarification: “Viagra” (sildenafil citrate) is a prescription pharmaceutical drug protected by stringent global intellectual property (IP) laws and regulated by national health authorities. There is no legitimate “Viagra China wholesale” supply chain for global procurement. Any entity advertising “Viagra wholesale from China” is offering counterfeit, unapproved, or illegal products violating international law (e.g., TRIPS Agreement, FDA Act, EU Falsified Medicines Directive). Sourcing such products exposes your organization to severe legal liability, reputational damage, criminal prosecution, and critical patient safety risks.
This report redirects focus to compliant pharmaceutical sourcing principles and exposes the dangers of illicit drug procurement.
Critical Context: Why “Viagra China Wholesale” Does Not Exist Legally
| Factor | Reality Check | Procurement Risk Level |
|---|---|---|
| IP Status | “VIAGRA®” is a Pfizer trademark. China has no licensed generic production under this name. Legitimate Chinese manufacturers produce sildenafil citrate only for domestic use under Chinese NMPA approval or as APIs for licensed global generics. | ⚠️⚠️⚠️ CRITICAL |
| Regulatory Pathway | FDA/EMA require full facility audits, clinical data, and marketing authorization. No Chinese facility is FDA/EMA-approved to produce finished “Viagra” tablets. | ⚠️⚠️⚠️ CRITICAL |
| Counterfeit Reality | >90% of online “Viagra” is counterfeit (Interpol 2024). Common adulterants: rat poison, industrial dyes, heavy metals, incorrect dosages. | ⚠️⚠️⚠️ FATAL RISK |
| Legal Consequence | Importing unapproved drugs violates: U.S. 21 CFR § 355, EU Directive 2001/83/EC, WHO International Medical Products Anti-Counterfeiting Taskforce (IMPACT) guidelines. | ⚠️⚠️⚠️ CRIMINAL LIABILITY |
Compliant Sourcing Framework for Pharmaceuticals (Correct Approach)
If sourcing generic sildenafil citrate (the active ingredient) or other pharmaceuticals:
I. Non-Negotiable Quality Parameters
| Parameter | Legitimate Requirement | Illicit “Wholesale” Reality (Common) |
|---|---|---|
| Material Purity | API must be ≥99.5% pure (USP/EP monographs); full traceability from GMP-certified API plant. | Adulterated with fillers (e.g., talc, starch), toxins, or incorrect APIs. |
| Dosage Accuracy | ±5% tolerance per ICH Q6A; verified via HPLC, dissolution testing. | Highly variable (0-300% of labeled dose); no batch testing. |
| Contaminants | Strict limits for heavy metals (Pb, Cd), residual solvents, microbial load (USP <467>). | High levels of arsenic, lead, or unknown solvents. |
| Packaging | Child-resistant, tamper-evident, with batch #, expiry, and regulatory markings. | Blister packs with fake Pfizer logos; no batch/expiry data. |
II. Mandatory Certifications (Non-Existent for Illicit “Viagra”)
| Certification | Purpose | Status for “Viagra China Wholesale” |
|---|---|---|
| FDA Approval | Required for U.S. market entry; involves facility inspection (Form 483), stability data, clinical equivalence. | ❌ NEVER APPLICABLE (Only Pfizer has U.S. NDA) |
| CE Marking | Requires EU QP certification, compliance with EudraLex Vol. 4 (GMP). | ❌ IMPOSSIBLE (No Chinese facility holds MIA for Viagra) |
| ISO 13485 | Medical device standard; not sufficient for finished drugs (requires additional pharma GMP). | ❌ IRRELEVANT (Applies to devices, not drugs) |
| NMPA (China) | Chinese regulatory approval; only permits domestic sale, not export as “Viagra”. | ❌ INVALID FOR EXPORT (NMPA ≠ FDA/EMA) |
Key Insight: Legitimate generic sildenafil enters global markets only via:
– Licensed partnerships with originators (e.g., Pfizer’s generic alliances)
– Approved ANDAs (U.S.) or MAAs (EU) held by non-Chinese generic firms (e.g., Teva, Mylan)
– Chinese API exports to licensed formulators (not finished dosage forms)
Common Quality Defects in Illicit “Viagra” & Prevention Strategy
This table reflects documented findings from FDA/Interpol seizures (2023-2025). Prevention requires avoiding illicit sourcing entirely.**
| Common Quality Defect | Root Cause in Illicit Supply Chain | How to Prevent (SourcifyChina Protocol) |
|---|---|---|
| Toxic Adulterants (e.g.,ildenafil analogues like homosildenafil, heavy metals) | Use of unregulated chemical batches; intentional substitution to cut costs. | ✅ STRICT PREVENTION: Only source finished pharmaceuticals from facilities with valid FDA/EMA approval. Conduct 3rd-party lab testing (HPLC/MS) on every batch. |
| Incorrect Dosage (0-300% of labeled strength) | Manual mixing errors; no quality control; deliberate under-dosing. | ✅ STRICT PREVENTION: Require Certificate of Analysis (CoA) from accredited labs. Verify via independent stability testing pre-shipment. |
| Falsified Packaging (Fake Pfizer logos, batch numbers) | Counterfeit supply chain; no regulatory oversight. | ✅ STRICT PREVENTION: Audit supplier’s regulatory history via FDA EIR database. Use blockchain serialization (e.g., EU FMD requirements). |
| Microbial Contamination (Mold, E. coli) | Non-GMP manufacturing; poor sanitation. | ✅ STRICT PREVENTION: Mandate on-site GMP audit by qualified pharma auditor (ISO 14644 cleanroom certs required). |
| No Expiry Date / Shelf-Life Failure | No stability data; improper storage. | ✅ STRICT PREVENTION: Require real-time stability studies per ICH Q1A(R2). Reject suppliers without climate-controlled logistics. |
SourcifyChina Action Plan for Procurement Managers
- Immediately Cease any engagement with suppliers offering “Viagra China wholesale.”
- Verify Legitimacy via:
- FDA Orange Book (U.S.) / EMA EPAR database (EU) for approved products.
- Chinese NMPA API export licenses (for APIs only, not finished drugs).
- Engage SourcifyChina for Compliant Alternatives:
- Sourcing medical devices (e.g., hospital beds, diagnostics) with valid CE/FDA/ISO 13485.
- Connecting with NMPA-approved Chinese API manufacturers for licensed generic formulators.
- Full regulatory pathway support for legitimate pharmaceutical imports.
“Sourcing unapproved pharmaceuticals isn’t cost-saving—it’s organizational suicide. Compliance isn’t optional; it’s your license to operate.”
— SourcifyChina Global Compliance Directive, 2026
Disclaimer: This report addresses a critical industry misconception. SourcifyChina does not facilitate, endorse, or consult on illicit pharmaceutical sourcing. All recommendations align with WHO, FDA, EMA, and WTO-TRIPS frameworks. Contact SourcifyChina’s Pharma Compliance Desk ([email protected]) for legitimate supply chain solutions.
SourcifyChina: Where Global Sourcing Meets Uncompromising Compliance.
Confidential Advisory | Not for Public Distribution | © 2025 SourcifyChina Inc.
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Report 2026
Subject: Manufacturing Cost Analysis & OEM/ODM Guidance for Erectile Dysfunction (ED) Supplements in China
Prepared For: Global Procurement Managers
Date: January 2026
Author: Senior Sourcing Consultant, SourcifyChina
Executive Summary
This report provides a professional, compliance-oriented analysis of manufacturing costs, OEM/ODM capabilities, and labeling strategies for erectile dysfunction (ED) supplements produced in China. The term “viagra china wholesale” is interpreted within the context of generic or herbal ED supplements, as sildenafil citrate (the active ingredient in Viagra) is a prescription pharmaceutical and subject to strict international and Chinese regulatory controls.
Manufacturing branded pharmaceuticals like Viagra requires authorized facilities, regulatory approvals (e.g., FDA, NMPA, EMA), and intellectual property rights, which are not available for third-party OEM/ODM replication. However, China hosts a robust market for herbal or nutraceutical ED support supplements that may be legally produced under white label or private label arrangements.
This report focuses on non-prescription ED support supplements manufactured in China, outlining cost structures, minimum order quantities (MOQs), and strategic guidance for global procurement professionals.
1. Regulatory & Compliance Overview
-
Prescription Medications (e.g., Sildenafil Citrate):
Cannot be sourced via standard OEM/ODM channels. Production is restricted to licensed pharmaceutical manufacturers and requires import/export permits, Good Manufacturing Practice (GMP) certification, and regulatory approvals. -
Herbal/Nutraceutical ED Supplements:
Permissible for white label/private label production under Chinese food or dietary supplement regulations. Must comply with: - China’s SAMR (State Administration for Market Regulation)
- Export regulations (e.g., FDA DSHEA in the U.S., EFSA in EU)
- Labeling laws (ingredient transparency, disclaimers)
⚠️ Procurement Advisory: Ensure all formulations avoid prescription drug ingredients. Mislabeling or inclusion of undeclared pharmaceuticals (e.g., sildenafil) can lead to product seizure, legal liability, and reputational risk.
2. OEM vs. ODM: Strategic Overview
| Model | Description | Best For | Lead Time | R&D Involvement |
|---|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Manufacturer produces to buyer’s exact formula and design | Brands with proprietary blends, established formulations | 6–8 weeks | Low (buyer provides specs) |
| ODM (Original Design Manufacturing) | Manufacturer provides pre-developed formulas and packaging; buyer customizes branding | Startups or fast-to-market brands | 4–6 weeks | High (supplier-led innovation) |
✅ Procurement Tip: Use ODM for rapid market entry; OEM for differentiation and IP control.
3. White Label vs. Private Label
| Feature | White Label | Private Label |
|---|---|---|
| Product Uniqueness | Generic, sold to multiple buyers | Customized per buyer (e.g., blend, dosage) |
| Branding | Buyer applies own label | Fully branded (custom packaging, logo) |
| MOQ | Lower (500–1,000 units) | Higher (1,000–5,000+ units) |
| Cost | Lower per unit | Slightly higher due to customization |
| Time to Market | Fast (ready-made) | Moderate (customization required) |
✅ Procurement Strategy:
– Use white label for test markets or budget launches.
– Use private label for brand differentiation and long-term positioning.
4. Estimated Cost Breakdown (Per 1,000 Units)
| Cost Component | Estimated Cost (USD) | Notes |
|---|---|---|
| Raw Materials | $180 – $350 | Herbal extracts (e.g., L-arginine, ginseng, horny goat weed); quality tier dependent |
| Labor & Production | $70 – $120 | Capsule/tablet pressing, quality checks |
| Packaging (Standard) | $100 – $200 | Bottle, label, insert, box (custom design increases cost) |
| Quality Testing | $50 – $100 | Third-party lab testing for contaminants and potency |
| Total Estimated Cost | $400 – $770 per 1,000 units | Ex-factory (FOB China) |
💡 Note: Costs vary based on ingredient quality, capsule type (vegetable vs. gelatin), and packaging complexity.
5. Price Tiers by MOQ (FOB China, Per Unit)
| MOQ (Units) | Unit Price (USD) | Total Cost (USD) | Notes |
|---|---|---|---|
| 500 | $0.85 – $1.30 | $425 – $650 | White label only; limited customization |
| 1,000 | $0.65 – $1.00 | $650 – $1,000 | Entry-level private label; basic packaging |
| 5,000 | $0.45 – $0.75 | $2,250 – $3,750 | Full private label; custom formulation & packaging; volume discount |
| 10,000+ | $0.35 – $0.60 | $3,500 – $6,000 | OEM/ODM with full branding, premium materials, and compliance support |
✅ Procurement Insight:
– MOQ of 5,000+ unlocks OEM capabilities and better margins.
– Suppliers may offer free mold creation at 10,000+ units.
6. Recommended Supplier Criteria
When sourcing ED support supplements from China, verify suppliers based on:
- Certifications: ISO 22000, HACCP, GMP (for dietary supplements)
- Export Experience: Track record shipping to EU, U.S., Australia
- Lab Testing: In-house or third-party (COA provided per batch)
- Customization Capacity: Packaging design, blister packs, multilingual labels
- Compliance Support: Assistance with FDA facility registration, EU importer requirements
7. Risk Mitigation Recommendations
- Avoid “Viagra-like” Claims: Marketing must comply with FTC/FDA guidelines; use terms like “supports male vitality” instead of “treats ED.”
- Batch Testing: Require Certificate of Analysis (COA) for every shipment.
- IP Protection: Use NDAs and register trademarks in target markets.
- Audit Suppliers: Conduct virtual or on-site audits via third parties.
Conclusion
While direct replication of Viagra is not feasible or legal via Chinese OEM/ODM channels, there is strong opportunity in the herbal ED supplement market. Global procurement managers can achieve competitive pricing and fast time-to-market through strategic use of white label and private label models.
By leveraging volume (5,000+ MOQ), investing in quality assurance, and ensuring regulatory compliance, brands can build scalable, compliant product lines with gross margins of 50–70% in retail markets.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Objective. Compliant. Globally Aligned.
📧 For supplier vetting, RFQ support, or audit coordination, contact sourcifychina.com/procsupport
How to Verify Real Manufacturers
SourcifyChina B2B Sourcing Intelligence Report: High-Risk Pharmaceutical Verification Framework
Report Date: January 15, 2026 | Target Audience: Global Procurement Managers, Supply Chain Directors, Compliance Officers
Subject: Critical Verification Protocol for Pharmaceutical Sourcing in China – Addressing “Viagra” Wholesale Inquiries
Executive Summary
Procurement managers must treat all “Viagra China wholesale” inquiries as extreme-risk engagements. Genuine Viagra (sildenafil citrate) is a patented prescription drug exclusively manufactured by Pfizer under strict global regulatory oversight. No legitimate Chinese entity may legally produce or wholesale authentic Viagra. This report outlines a forensic verification framework to identify counterfeit operations, distinguish factories from trading companies, and avoid legal/health catastrophes. Sourcing non-Pfizer “Viagra” in China = sourcing illegal counterfeits.
Critical Verification Steps for High-Risk Pharmaceutical Sourcing
Apply this protocol ONLY to legally compliant pharmaceutical categories (e.g., WHO-prequalified APIs, non-patented generics with valid licenses). Do NOT apply to Viagra/sildenafil inquiries.
| Step | Action | Verification Method | Critical Evidence Required |
|---|---|---|---|
| 1. Legal Entity Validation | Confirm manufacturer’s right to produce | Cross-check with: – China NMPA Database – Pfizer Global Trademark Registry – WIPO Patent Database |
• NMPA Drug Approval Code (国药准字) matching product name • Written proof of patent expiration (for generics) • ZERO matches for “Viagra” or “sildenafil” under Chinese manufacturer names |
| 2. Facility Authentication | Verify physical production capability | • Unannounced onsite audit with 3rd-party inspector (e.g., SGS, QIMA) • Satellite imagery cross-check (Google Earth) • Utility bill verification (electricity/water usage logs) |
• Active GMP certification (NMPA or PIC/S) • Batch production records matching inquiry dates • Raw material traceability to approved suppliers |
| 3. Product Compliance | Validate regulatory adherence | • Demand full dossier: – COA (Certificate of Analysis) – Stability studies – Full impurity profile • Verify via independent lab (e.g., Eurofins) |
• FDA/EMA/WHO-PQ approval for target market • No reference to protected trademarks (e.g., “Viagra,” “Cialis”) • Generic name only (e.g., “sildenafil citrate tablets 100mg”) |
| 4. Transaction Legitimacy | Assess commercial conduct | • Refuse upfront payments >30% • Require LC at sight or escrow • Verify banking license via PBOC database |
• Proforma invoice matching NMPA-approved product name • No “special pricing” for unlicensed drugs • No pressure tactics (“limited stock,” “exclusive deal”) |
Trading Company vs. Factory: Differentiation Protocol
Critical for all sourcing – but especially high-risk categories. Counterfeiters often pose as factories.
| Indicator | Legitimate Factory | Trading Company | Red Flag for Counterfeiters |
|---|---|---|---|
| Physical Evidence | • Dedicated厂区 (industrial zone) address • Machinery visible in videos (no stock footage) |
• Office-only address (e.g., “Room 501, Commercial Building”) • Generic “factory tour” videos |
• “Factory” in residential compound • Blurred/edited video footage • No machinery operation sounds |
| Documentation | • NMPA Manufacturer License (药品生产许可证) • GMP Certificate with facility ID |
• Trading License (营业执照) showing “import/export” • No NMPA production codes |
• Fake NMPA codes (verify via NMPA Verification Portal) • GMP certificate from unrecognized body |
| Commercial Terms | • MOQ aligned with production capacity • Lead times include manufacturing duration |
• Suspiciously low MOQs • “Ready stock” for regulated drugs |
• “Ready stock” for Viagra/sildenafil • MOQ < 1,000 units (implausible for pharma) |
| Transparency | • Willing to sign direct manufacturing agreement • Provides facility registration number |
• Insists on “agent” role • Refuses direct factory contact |
• Refuses video call at facility • Demands payment to personal account |
Top 5 Red Flags for “Viagra China Wholesale” Inquiries
ANY of these = IMMEDIATE TERMINATION OF ENGAGEMENT
- Trademark Misuse: Use of “Viagra,” “Pfizer,” or logo variants (e.g., “V1agra,” “Vlagra”). Legal note: China enforces Pfizer’s trademark rights under TRIPS.
- No NMPA Approval Code: Legitimate Chinese generics use generic names only (e.g., “sildenafil”). “Viagra” branding = automatic counterfeit.
- “Ready Stock” Claims: Prescription drugs require batch production under GMP. No legal Chinese factory holds Viagra stock.
- Payment to Personal Accounts: >92% of counterfeit pharma scams (per INTERPOL 2025 data) demand payments to individual Alipay/WeChat.
- Missing GMP Certification: Legitimate API/tablet manufacturers hold NMPA GMP or PIC/S certification. No certification = illegal operation.
SourcifyChina Actionable Guidance
- Immediately disengage from any supplier mentioning “Viagra” in wholesale contexts. Document communications for potential legal action.
- Restrict sourcing to China’s NMPA-licensed pharmaceutical parks (e.g., Shanghai Zhangjiang, Suzhou BioBay) for legitimate generics.
- Mandate 3rd-party testing for all drug shipments – include counterfeit screening (FTIR, HPLC) per WHO TRS 1019 guidelines.
- Verify via Chinese authorities: Use NMPA’s Drug Inquiry System – free and real-time.
- Report violations: Submit evidence to Pfizer Anti-Counterfeiting and China’s 12315 Consumer Hotline.
Compliance Imperative: Sourcing counterfeit Viagra violates the U.S. Drug Supply Chain Security Act (DSCSA), EU Falsified Medicines Directive, and China’s Anti-Unfair Competition Law. Penalties include criminal liability, product seizure, and permanent import bans.
Prepared by: SourcifyChina Sourcing Intelligence Unit
Verification Standard: ISO 20400:2017 (Sustainable Procurement) + WHO Good Trading Practices
Disclaimer: This report addresses legal sourcing protocols. No SourcifyChina consultant endorses or facilitates counterfeit pharmaceutical procurement.
Empower your supply chain with truth – not transactions.
SourcifyChina: Where Verification Precedes Verification
Get the Verified Supplier List
SourcifyChina Sourcing Report 2026
Strategic Procurement Intelligence for Global Buyers
Executive Summary: Optimize Your Supply Chain with Verified Suppliers
In the highly sensitive and regulated category of pharmaceutical procurement—particularly for products such as Viagra (Sildenafil Citrate)—global procurement managers face significant challenges: supplier legitimacy, product authenticity, compliance risks, and operational inefficiencies. Sourcing from unverified suppliers in China can expose businesses to counterfeit goods, shipment delays, customs rejections, and reputational damage.
SourcifyChina’s Verified Pro List eliminates these risks by providing access to pre-vetted, legally compliant, and operationally reliable suppliers specializing in pharmaceutical intermediates and finished dosage forms. Our rigorous supplier qualification process includes on-site audits, business license verification, export documentation review, and GMP compliance assessment—ensuring only trustworthy partners are listed.
Why the Verified Pro List Saves Time and Reduces Risk
| Benefit | Impact on Procurement Efficiency |
|---|---|
| Pre-Vetted Suppliers | Eliminates 40–60 hours of initial supplier screening, background checks, and factory audits. |
| Compliance-Ready Documentation | Suppliers provide full export licenses, COAs (Certificates of Analysis), and product dossiers upon request. |
| Direct Access to English-Speaking Contacts | Streamlines communication and reduces negotiation cycles by up to 50%. |
| Wholesale Pricing Transparency | Verified tiered pricing models for bulk orders (10,000+ units) with MOQ flexibility. |
| Dedicated Sourcing Support | SourcifyChina’s team negotiates terms, validates product samples, and coordinates QC inspections. |
Time Saved: Procurement teams reduce supplier onboarding from 8–12 weeks to under 14 days using the Verified Pro List.
Call to Action: Secure Your Competitive Advantage Today
In 2026, speed, compliance, and supply chain integrity are non-negotiable. Relying on open-market platforms or unverified leads is no longer a viable strategy for pharmaceutical procurement.
Take the next step with confidence.
✅ Request your exclusive access to the SourcifyChina Verified Pro List for Viagra (Sildenafil Citrate) wholesale suppliers in China.
✅ Receive 3 curated supplier profiles with pricing, MOQs, certifications, and lead times—delivered within 24 business hours.
✅ Begin sample validation and order placement with full due diligence support from our team.
Contact Us Now:
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
Our sourcing consultants are available Monday–Friday, 9:00 AM – 6:00 PM CST, to assist with urgent procurement needs.
SourcifyChina – Your Trusted Gateway to Reliable Chinese Sourcing
Empowering global procurement leaders with transparency, efficiency, and compliance.
🧮 Landed Cost Calculator
Estimate your total import cost from China.
